Compound library
16 research compounds. Each page carries the dosing on record, the evidence split, reported effects and its graded pairings.
BPC-157A pentadecapeptide studied mostly in animal models of tissue injury. Human evidence is small and uncontrolled, and no regulator ha
CJC-1295A long-acting GHRH analogue studied for growth-hormone release. Two early human trials measured hormone levels; no human study her
EpithalonA tetrapeptide studied for aging biology. Most evidence is animal or laboratory, with one older controlled clinical study in a ret
GHK-CuA naturally occurring copper peptide studied mostly for skin remodeling and wound healing. Its strongest human result is an older
GlutathioneA tripeptide antioxidant made in the body and studied in many small human trials. No approved therapeutic use appears here, and th
IpamorelinA selective growth-hormone secretagogue and ghrelin-receptor agonist. Outcome data are animal, and two completed human trials repo
MOTS-cA mitochondrial-derived peptide studied mainly for metabolism in mice. Human data are observational only, and no completed human t
MT-2A synthetic melanocortin receptor agonist studied for skin pigmentation. The human records here are case reports of harm after unr
PT-141A melanocortin receptor agonist with one approved use and a disputed effect size. It has one pairing in this atlas from a study th
RetatrutideA single peptide that activates the GIP, GLP-1 and glucagon receptors. It has the strongest human evidence in this atlas and, as o
SelankA heptapeptide studied for anxiety. Two small randomized trials in anxiety disorders report improvement, and the rest of the evide
SemaxA heptapeptide studied for cognition and neuroprotection. The outcome evidence is mostly animal, and the human records are small i
SLU-PP-332A synthetic exercise mimetic studied in mice for metabolism, heart failure and kidney aging. No human has been given it in this se
TB-500A short fragment of thymosin beta-4. Almost all outcome data are animal or laboratory, and the one human randomized trial used the
TesamorelinA GHRH analogue and the one FDA-approved compound in this atlas, cleared for a specific HIV-related use. Evidence outside that use
TirzepatideAn approved dual-incretin medicine with strong human evidence. This atlas covers it for research context only; its affiliate partn